SLC5A2 and type 2 diabetes mellitus: A significant aspect of this study is the broader applicability of SGLT2 inhibitors beyond T2DM, as recent studies highlight their benefits in managing CKD and congestive heart failure (CHF) across adult populations [48, 49].